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Y gastric bypass (RYGB) induce substantial weight loss and
improve glycemic control in patients with type 2 diabetes, but
it is not clear whether these occur via the same mechanisms.
We compared absorption rates of glucose and protein, as well
as proﬁles of gastro-entero-pancreatic hormones, in patients
who had undergone SG or RYGB vs controls. METHODS: We
performed a cross-sectional study of 12 patients who had
undergone sleeve gastrectomy, 12 patients who had under-
gone RYGB, and 12 individuals who had undergone neither
surgery (controls), all in Denmark. Study participants were
matched for body mass index, age, sex, and postoperative
weight loss, and all had stable weights. They received
continuous infusions of stable isotopes of glucose, glycerol,
phenylalanine, tyrosine, and urea before and during a mixed
meal containing labeled glucose and intrinsically
phenylalanine-labeled caseinate. Blood samples were collected
for 6 hours, at 10- to 60-minute intervals, and analyzed.
RESULTS: The systemic appearance of ingested glucose wasfaster after RYGB and SG vs controls; the peak glucose
appearance rate was 64% higher after RYGB, and 23% higher
after SG (both P < .05); the peak phenylalanine appearance rate
from ingested casein was 118% higher after RYGB (P < .01),
but similar between patients who had undergone SG and con-
trols. Larger, but more transient increases in levels of plasma
glucose and amino acids were accompanied by higher secretion
of insulin, glucagon-like peptide 1, peptide YY, and cholecys-
tokinin after RYGB, whereas levels of ghrelin were lower after
SG, compared with RYGB and controls. Total 6-hour oral re-
covery of ingested glucose and protein was comparable among
groups. CONCLUSIONS: Postprandial glucose and protein ab-
sorption and gastro-entero-pancreatic hormone secretions
differ after SG and RYGB. RYGB was characterized by accel-
erated absorption of glucose and amino acids, whereas protein
metabolism after SG did not differ signiﬁcantly from controls,
suggesting that different mechanisms explain improved gly-
cemic control and weight loss after these surgical procedures.
ClinicalTrials.gov ID NCT03046186.
WHAT YOU NEED TO KNOW
BACKGROUND AND CONTEXT
Sleeve gastrectomy and gastric bypass induce
substantial weight loss and improved glycemic control,
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Emptying; Protein Digestion.
oux-en-Y gastric bypass (RYGB) and sleeve gas-
but it is unknown whether the mechanisms via which
these procedures act are similar.
NEW FINDINGS
Absorption of glucose and protein was greatly
accelerated after gastric bypass and only modestly
accelerated after sleeve gastrectomy. Insulin, GLP-1,
PYY, and CCK secretion also differed markedly between
the procedures.
LIMITATIONS
The study was performed as a cross-sectional study.
However, this design was chosen to examine the
surgical patients in the weight-stable phase following a
matched weight loss.
IMPACT
Different mechanism may underlie the beneﬁcial effects of
the two surgical procedures.
Abbreviations used in this paper: AA, amino acid; ANOVA, analysis of
variance; AUC, area under the curve; BMI, body mass index; CCK,
cholecystokinin; EGP, endogenous glucose production; FFM, fat-free
mass; GIP, glucose-dependent insulinotropic polypeptide; GLP-1,
glucagon-like peptide 1; iAUC, incremental area under the curve; ISR,
insulin secretion rate; PYY, peptide YY; RYGB, Roux-en-Y gastric bypass;
SG, sleeve gastrectomy; Ra, rate of appearance; Rd, rate of
disappearance.
Most current article
© 2019 by the AGA Institute. Published by Elsevier Inc. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
0016-5085
https://doi.org/10.1053/j.gastro.2019.01.262Rtrectomy (SG) both induce major weight loss and
recovery from obesity-associated comorbidities, including
type 2 diabetes.1,2 A recent randomized controlled trial
showed comparable weight loss after SG and RYGB,3 while
another study demonstrated only slightly larger weight loss
after RYGB, below the prespeciﬁed threshold for clinical
signiﬁcance, at 5 years after surgery.4 Also improvements
in glycemic control have been suggested to be comparable
between the 2 procedures,2 or only slightly better after
RYGB.5 The physiological mechanisms behind weight loss
and improved glycemic control after SG are studied less
than those after RYGB. The comparable clinical outcomes
may seem surprising, given the marked post-surgical
anatomical differences between the procedures. After SG,
the only change is a longitudinal excision of the major
curvature of the stomach, leaving a narrow tube for
nutrient passage; importantly, the pyloric sphincter is
preserved after SG. By contrast, after RYGB, there is an
extensive rearrangement of the upper gastrointestinal tract,
including the creation of a small gastric pouch and bypass
of the stomach and upper small intestine, resulting in un-
impeded pouch emptying and accelerated entry of nutri-
ents into the small intestine. The latter has important
consequences. A greatly enhanced absorption of glucose
and protein is seen,6–9 which is accompanied by exagger-
ated meal-related release of several gut hormones involved
in appetite regulation and glucose homeostasis, including
the anorexigenic glucagon-like peptide 1 (GLP-1), peptide
YY (PYY), cholecystokinin (CCK), and oxyntomodulin,
whereas secretion of the orexigenic ghrelin is reported to
be attenuated, increased, or unchanged after RYGB.10–12
The sum of these hormonal alterations are thought to be
important for the decreased appetite and weight loss seen
after RYGB.13 The improved glycemic control arises from a
combination of factors, including increased hepatic and
peripheral insulin sensitivity,14 and improved meal-induced
insulin secretion, facilitated by exaggerated GLP-1
secretion.15
Accelerated gastric emptying and enhanced glucose
absorption are also reported after SG,9,16 and an
increased secretion of GLP-1, comparable to that seen
after RYGB, has been reported in some,17–19 but not
all,20–22 studies. Using the GLP-1 receptor antagonist,
exendin 9-39, it has been demonstrated that GLP-1
affects b-cell function and glucose tolerance after both
RYGB and SG.15,23 However, both SG and RYGB remain
effective in GLP-1 receptor knockout mice,24,25 suggest-
ing that additional mechanisms are involved. Both
ghrelin and bile acids have been proposed to play a role
for weight loss and improved glucose metabolism after
RYGB and SG,19,26,27 but the role remains unclear in
humans.
Thus, the physiological changes after SG and RYGB are
not fully clariﬁed. Modiﬁed nutrient delivery to theintestine and accelerated absorption and metabolism of
nutrients, as well as altered gut hormone secretion, could
be critically important for the post-bariatric changes. We
performed a detailed analysis of the postprandial absorp-
tion and metabolism of glucose and protein after SG and
RYGB using a variety of stable, isotopically labeled me-
tabolites in connection with a mixed meal containing
intrinsically labeled protein and glucose tracers. Further-
more, gastro-entero-pancreatic hormonal secretion was
assessed.
Previously published studies have investigated SG- and
RYGB-operated individuals separately,6,7,28,29 have been
performed early postoperatively during an ongoing weight
loss,6,7,9 or lacked a proper control group.
Therefore, we chose to study SG- and RYGB-
operated subjects who were individually matched in
terms of postoperative weight loss and were in
the weight-stable phase, as well as to compare these
patients with a group of unoperated body mass index
(BMI)–matched control subjects. We hypothesized
that glucose and protein absorption rates would
be increased after SG compared with unoperated
controls.
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Subjects
Twelve subjects who had undergone uncomplicated SG
more than 12 months before inclusion were recruited from the
Bariatric Surgery Program at Copenhagen University Hospital
Hvidovre (Hvidovre, Denmark). For each SG subject, 1 subject
who had undergone uncomplicated RYGB more than 12
months earlier was recruited based on individual matching in
terms of current BMI, age, sex, and preoperative BMI. In
addition, 12 unoperated control subjects also individually
matched in terms of BMI, age, and sex were recruited through
local advertisement. All subjects were weight-stable (±3 kg
during the last month) and had normal glucose tolerance
(fasting plasma glucose <6.1 mmol/L and hemoglobin A1c
<48 mmol/mol), and none of the operated subjects had a
history of diabetes before surgery. The exclusion criteria were
inadequately treated thyroid disease, serious heart or respi-
ratory illness, hemoglobin <6.5 mmol/L, pregnancy, and
breastfeeding.
Surgical Techniques
Using standard laparoscopic procedures, SG and RYGB were
performed at the Department of Surgical Gastroenterology at
Copenhagen University Hospital at Hvidovre (Hvidovre,
Denmark) by experienced surgeons. RYGB was created via the
formation of a 4  6.5 cm gastric pouch with a 75-cm bil-
iopancreatic limb and a 125-cm Roux limb. SG was performed
using a standard laparoscopic technique, with division of the
greater curvature of the stomach via the use of a linear stapler
4 cm from the pylorus to the angle of His along a 40-Ch orally
inserted gastric tube.
Ethics
The study was approved by the Regional Ethical Committee
of the Capital Region (Protocol number: H-15009263) and by
the Danish Data Protection Agency. It was performed in
accordance with the Helsinki declaration and was registered at
ClinicalTrials.gov (NCT03046186). Written informed consent
was obtained from all participants before inclusion. All co-
authors had access to the study data and have reviewed and
approved the ﬁnal manuscript.
Study Design
Dual-energy x-ray absorptiometry was used to assess fat-
free mass (FFM). Subjects were instructed to avoid stren-
uous physical activity for 2 days before the experimental day
and to follow their normal dietary habits. On the experimental
day, patients arrived after an overnight fast (10–12 hours) and
were weighed and placed in a hospital bed in a reclined po-
sition. No physical activity was allowed throughout the day.
Intravenous catheters were inserted into antecubital veins: in
one arm for tracer infusion and in the other, which was kept
warm in a heating pad to “arterialize” the blood, for blood
sampling. Three fasting blood samples were drawn (time –130
to –120) to determine the abundance of natural occurring
isotopes. A priming bolus of L-[ring-D4] tyrosine (0.46 mmol/
kg FFM) was injected, and a primed-continuous infusion of
[6,6-D2] glucose (prime 17.6 mmol/kg FFM, continuous 0.4
mmol/kg FFM/min), [1,1,2,3,3-D5] glycerol (prime 1.5 mmol/kgFFM, continuous 0.1 mmol/kg FFM/min), L-[ring-D5] phenyl-
alanine (prime 3 mmol/kg FFM, continuous 0.07 mmol/kg
FFM/min ), L-[ring-3,5-D2] tyrosine (prime 2.3 mmol/kg FFM,
continuous 0.04 mmol/kg FFM/min), and [15N2] urea (prime
84 mmol/kg FFM, continuous 0.15 mmol/kg FFM/min) was
provided with a volumetric infusion pump (mVP5000;
Arcomed Ag, Kloten, Switzerland) for a total of 8 hours. The
actual concentrations of the tracers were measured in the
infused solution and used in the subsequent calculations.
Stable isotopes for the intravenous infusions (from Cambridge
Isotope Laboratories, Andover, MA) were prepared under
sterile conditions by the Capital Region Pharmacy (Herlev,
Denmark).
After 1.5 hours of basal tracer infusion, basal blood samples
were drawn (time –30, –15, and 0) for the determination of
basal steady-state tracer enrichments and hormone concen-
trations. At time ¼ 0, a liquid mixed meal (200 mL, 400 kcal,
carbohydrate 50 E%, protein 15 E%, and fat 35 E%) was
provided. It was composed of glucose (47.8 g dextrose
monohydrate þ 2.7 g [U-13C6]glucose), rapeseed oil (14.1 g),
and caseinate that was intrinsically labeled (16.7 g) with 11.8%
[15N]phenylalanine enrichment of the phenylalanine and
ﬂavored with 1 g of raspberry aroma. Intrinsically labeled
caseinate was produced via an infusion of [15N]-phenylalanine
into one lactating cow to obtain [15N]-phenylalanine-enriched
milk, from which the caseinate fraction was obtained at Arla
Foods (Nørre Vium, Denmark) following a previously described
procedure.30 One gram of paracetamol (Pamol; Nycomed,
Roskilde, Denmark) was added to the ﬁrst 2 cl of the meal to
estimate gastric emptying, and the rest of the meal was
consumed evenly over 20 minutes under supervision. Blood
sampling was continued frequently for 6 hours relative to start
of the test meal (at 10, 20, 30, 45, 60, 75, 90, 120, 150, 180, 240,
300, and 360 minutes).Sample Collection and Laboratory Analyses
Blood was collected into chilled EDTA tubes containing a
speciﬁc DPP-4 inhibitor (valine-pyrrolidide, ﬁnal concentra-
tion of 0.01 mM; a gift from Novo Nordisk, Bagsværd,
Denmark) for the analysis of GLP-1, glucose-dependent insu-
linotropic polypeptide (GIP), glucagon, PYY, and ghrelin. The
storage of samples and immunoassays for total GLP-1, GIP,
and glucagon in EDTA plasma were carried out as described
previously.31 Total PYY and total ghrelin were measured in
EDTA plasma, and active ghrelin was measured in EDTA
plasma treated with 1 N hydrochloric acid (5 mL/mL plasma)
and phenylmethylsulfonyl ﬂuoride (20 mL/mL plasma) using
a Millipore RIA kit (cat. no. PYYT-66HK, GHRT-89HK and
GHRT-88HK; Millipore, Billerica, MA). CCK was measured in
EDTA plasma as reported previously.32 Serum insulin, C-
peptide, and fatty acid concentrations were determined via
Immulite 2000 analyzer (Siemens Healthcare Diagnostics,
Tarrytown, NY). Metabolite concentrations and enrichments
were analyzed with a liquid chromatography triple mass
spectrometer. Liquid chromatography triple mass spectrom-
etry analysis of glucose and glycerol (Accela þ Surveyer
pumps; TSQ Vantage, ThermoFisher Scientiﬁc, San Jose, CA)
and amino acids (AA) (Double Pump Ultimate3000, TSQ
Quantiva, ThermoFisher Scientiﬁc) was performed as
described previously.33,34
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Basal concentrations were calculated as the mean of 3 basal
samples. The area under the curve (AUC) was calculated using
the trapezoidal rule and incremental AUC (iAUC) with sub-
tracted basal values. Total metabolite rate of appearance (Ra)
and rate of disappearance (Rd) were estimated via standard
Steele non–steady-state equations. Equations and detailed de-
scriptions of calculations can be found in the Supplementary
Material. In short, oral Ra glucose (Raglu) was calculated from
the [U-13C6] glucose enrichment multiplied with the total Raglu.
Endogenous Raglu (endogenous glucose production [EGP]) was
calculated by subtracting oral Raglu from total Raglu. The oral Ra
of phenylalanine (Raphe) and endogenous Raphe were calculated
likewise using enrichment of [15N]-phenylalanine. The oral re-
covery of glucose and phenylalanine represents the total sys-
temic appearance over 6 hours. This is calculated from the AUC
of the oral Ra and is expressed as a percentage of the amount of
ingested glucose or phenylalanine in the meal.
To estimate whole-body protein kinetics, endogenous Raphe
was used as an index of whole-body protein breakdown. The
rate of phenylalanine-to-tyrosine hydroxylation (calculated as
the product of total Ratyr and D4-tyrosine/D5-phenylalanine-
ratio) is the rate-limiting step in phenylalanine oxidation and
was used as an estimate of oxidative loss; hence, whole-body
protein synthesis was calculated as Rdphe minus the rate of
phenylalanine-to-tyrosine hydroxylation. Net protein synthesis
was calculated as whole-body protein synthesis minus whole-
body protein breakdown. Raurea represents irreversible loss
of nitrogen from hepatic AA degradation and was used as an
estimate of net whole-body protein catabolism.
Prehepatic insulin secretion rates (ISRs) were derived via
deconvolution of peripheral C-peptide concentrations, as
described previously.35 b-Cell glucose sensitivity was calculated
as the slope of the linear relation between ISR and the corre-
sponding plasma glucose value for each individual.13 These
slopes were calculated separately for increasing and decreasing
values of plasma glucose. Insulin sensitivity was estimated as
1/Homeostatic Model Assessment of Insulin Resistance, and the
Hepatic Insulin Sensitivity Index was calculated as the product
of EGP and basal C-peptide.14 b-Cell function was evaluated
using the disposition index, calculated as the products of 1/
Homeostatic Model Assessment of Insulin Resistance and b-cell
glucose-sensitivity for the upslope and downslope of the
glucose concentration curve separately.
Suppression of EGP, free fatty acids, and glycerol in the
postprandial phase was calculated as the difference between
nadir and basal levels and expressed as a percentage of the
basal level. Excess BMI loss was calculated as (preoperative
BMI – current BMI) / (preoperative BMI – 25)  100%.
Gastric/pouch emptying was estimated using time to peak
of paracetamol concentrations (Tmax pcm). We validated this
measure of gastric/pouch emptying in a separate study with
comparable groups of SG- and RYGB-operated and unoperated
controls.36 In this study, a fatty liquid meal (558 kcal carbo-
hydrate 10 E%, protein 7 E%, and fat 83 E%) thoroughly mixed
with 1 g of paracetamol (Pamol; Nycomed) and a radiolabeled
tracer 111In-DTPA (4 MBq) was ingested uniformly over 10
minutes. Scintigraphy (Symbia Intevo, Siemens Healthineers,
Erlangen, Germany) and blood sampling were frequently per-
formed for 300 minutes to estimate Tmax pcm and gastric/
pouch mean emptying time, an integrated measure of the entireemptying process37 calculated as the area under the gastric
retention (fraction)  time curve.
Statistical Analysis
Sample size was calculated to n ¼ 8 in each group to detect
a signiﬁcant difference in the primary outcome, peak Ra of oral
glucose, between SG and controls with 80% power and a 2-
sided a-error of .05, assuming that the changes after SG
would be 50% of the changes after RYGB.6 However, because
our power calculation was based on a study involving only data
from RYGB-operated subjects (as these were the only data
available), we chose to include 12 in each group.
The postprandial time courses of glucose, glycerol,
phenylalanine, tyrosine, and urea kinetics were analyzed in
repeated-measurement linear mixed-effects models using time,
group, time  group interaction, and an additional match var-
iable (specifying the pairing of the individually matched sub-
jects) as categorical ﬁxed effects and individual subjects as a
random effect. The analysis of variance (ANOVA) for time 
group interaction was reported as the primary readout. Loga-
rithmic transformation was used in the case of a skewed dis-
tribution for optimal model ﬁt, and a Shapiro-Wilk test was
used to test for normal distribution of residuals. Non-repeated
data (basal and peak concentrations and AUCs) were analyzed
via two-way ANOVA, with group and match variable treated as
ﬁxed effects, followed by a post-hoc Tukey’s test for multiple
comparisons to determine differences between the groups.
Statistical analysis was performed in R, version 3.2.3 (www.R-
project.org), with the “nlme” package for linear mixed-effects
models. A P value <.05 was considered signiﬁcant. All values
are mean ± SEM unless otherwise stated.
Results
Characteristics of Subjects
Twelve SG-operated, 12 RYGB-operated, and 12 unop-
erated control subjects were included. The groups were
matched 1:1:1 in terms of age (SG: 42.8 ± 3.3 years, RYGB:
43.0 ± 2.1 years, controls: 44.9 ± 3.4 years; ANOVA P ¼
.86), sex (9 women in each group), and BMI (SG: 33.4 ± 2.4
kg/m2, RYGB: 33.5 ± 2.1 kg/m2, controls: 33.4 ± 1.7 kg/
m2; P ¼ .99). In addition, the surgical groups were matched
in terms of preoperative BMI (SG: 44.0 ± 2.0 kg/m2 vs
RYGB 44.1 ± 2.4 kg/m2; P ¼ .96) and, accordingly, post-
operative excess BMI loss was comparable (SG: 60% ± 8%
vs RYGB: 61% ± 7%; P ¼ .94). FFM did not differ between
groups (SG: 61 ± 4 kg, RYGB: 64 ± 5 kg, controls: 60 ± 4
kg; P ¼ .85) and neither did the trunk-to-leg fat percent
ratio. Time from surgery was slightly higher in the RYGB
group vs SG (median, 2.1 [IQR, 0.3] years vs median, 1.8
[IQR, 0.6]; P ¼ .04).
Glucose Kinetics
Basal concentrations of plasma glucose were similar in
the 2 surgical groups and were lower compared with
controls (P < .02 vs RYGB, P ¼ .13 vs SG). Postprandial
glucose excursions differed signiﬁcantly between the 3
groups, with higher peak (P < .01 vs controls, P ¼ .13
vs SG) and lower nadir (P < .01 vs controls, P ¼.07 vs SG)
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comparable between all groups (ANOVA P ¼ .43)
(Figure 1, Table 1).
The appearance of oral glucose in the systemic circula-
tion was faster and had a higher peak oral Raglu in the 2
surgical groups compared with controls, but the appearance
of glucose also differed between SG and RYGB, with a 33%
higher peak oral Raglu after RYGB (P ¼ .002 vs SG). As for
the iAUC of plasma glucose, the overall 6-hour recoveries of
the meal-derived glucose in the systemic circulation during
the entire test period were similar between groups, but the
recovery within the ﬁrst postprandial hour was 31% ± 1%
in the RYGB group, compared with 23% ± 1% and 14% ±
1% of ingested glucose in the SG and control groups (both
P < .001 vs RYGB).
Basal EGP was comparable between groups, whereas the
postprandial time course differed (time  group interaction
ANOVA P < .001), with less suppression and earlier post-
suppression rise in the RYGB group resulting in slightly
higher EGP at the end of the study day compared with both
the SG and control group (both P < .05, Figure 1). The
postprandial curves for total Raglu were signiﬁcantly
different between groups (P < .01 for all comparisons), with
highest peak value being seen after RYGB, followed by SG,
and lowest being seen in the control group. Also, a faster
decline after the peak was seen in the 2 surgical groups.
Total Rdglu was slightly delayed compared with total Ra but
followed the same group kinetics.
Postprandial lactate followed plasma glucose excursions
and differed between all groups, with highest lactate for-
mation after RYGB (Table 1, Figure 1).Insulin and Insulin Secretion Rates
Insulin and C-peptide concentrations were lower in the
fasting state after RYGB compared with controls. Peak
values for both insulin and ISR were greatly exaggerated
after RYGB, whereas neither basal nor peak values differed
between SG and controls (Table 1, Figure 2). However, the
iAUC of insulin and ISR values were comparable between
the groups.Insulin Sensitivity, Clearance, and b-Cell Function
Insulin sensitivity, evaluated by 1/Homeostatic Model
Assessment of Insulin Resistance, was higher in the sur-
gical groups (P ¼ .03 for RYGB vs controls, P ¼ .07 for SG
vs controls), whereas Hepatic Insulin Sensitivity Index,
which mainly reﬂects hepatic insulin sensitivity, was
signiﬁcantly higher only after RYGB, with no difference
between SG and controls (P ¼ .67). b-Cell glucose sensi-
tivity did not differ between groups either on the upslope
or the downslope of the glucose concentration curves.
However, when evaluated as the disposition index, b-cell
function was comparable in the surgical groups and was
numerically higher compared with controls, although only
the difference between RYGB and controls reached statis-
tical signiﬁcance on the downslope of the glucose con-
centration (Table 1).Oral Protein Absorption and Amino Acid
Concentration Kinetics
Basal plasma phenylalanine was comparable in all
groups. After the meal, a more pronounced rise in phenyl-
alanine concentrations was seen in RYGB subjects, as
demonstrated by a higher peak concentration than in both
SG and controls (Figure 3). In the SG group, the peak
phenylalanine concentration was comparable to that in
controls (P ¼ .99), but the peak was reached faster after
meal intake. Phenylalanine AUCs were comparable between
groups. Total Raphe kinetics showed the same pattern as
phenylalanine concentrations, with a greatly exaggerated
peak in total Raphe only after RYGB.
The systemic appearance rates of phenylalanine from
the ingested caseinate (oral Raphe) differed signiﬁcantly
between the groups, with 118% and 61% higher peak oral
Raphe after RYGB compared with controls and SG, respec-
tively (both P < .01). The peak oral Raphe in the SG-operated
subjects was reached more quickly but was only numeri-
cally higher compared with controls (P ¼ .22). The oral 6
hours recovery of the ingested protein was comparable
between the groups during the entire postprandial period,
with 60% ± 4%, 55% ± 4%, and 54% ± 4% of ingested
phenylalanine appearing in the systemic circulation in
RYGB, SG, and controls, respectively. However, the systemic
appearance of the ingested phenylalanine was greatly
accelerated after RYGB, with signiﬁcantly enhanced oral
recovery within the ﬁrst postprandial hour (Table 2).
The concentrations of total AA did not differ between
groups in the fasting state but increased more postprandi-
ally after RYGB than after SG and in controls (both P < .01
for peak concentrations); essential AA and alanine followed
the same pattern. In contrast, branched-chain AAs were
lower in the fasting state after both RYGB and SG, but the
peak was higher after RYGB. Glutamate and glutamine
concentrations did not differ between groups (Figure 4).Whole-Body Protein Metabolism
Whole-body protein breakdown and synthesis in the
basal state were comparable between groups. After meal
intake, whole-body protein breakdown increased slightly
after RYGB. Likewise, the phenylalanine-to-tyrosine oxida-
tion rate was higher in the early postprandial period after
RYGB, but was comparable between groups when calculated
as percentage of total Raphe (ANOVA >0.45 for all between-
group differences in postprandial trajectories, Figure 3).
Concomitantly, protein synthesis was even more increased,
resulting in a greatly increased positive net protein balance
after RYGB during the ﬁrst 3 postprandial hours (AUC0–180
of net protein balance: RYGB: þ190 g protein/d, SG: þ110,
controls: þ30, P < .01 RYGB vs controls, P ¼ .13 RYGB vs
SG), whereas no difference was found in the AUC of net
protein balance between groups during the entire post-
prandial period (ANOVA P ¼ .60). However, it should be
noted that the postprandial anabolic phase (positive net
protein balance) was approximately 2.5 hours in these
RYGB-operated subjects compared with approximately 4
hours for SG and controls.
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Table 1.Fasting and Incremental Area Under the Curve for Plasma Glucose, Lactate, Insulin, Insulin Secretion Rates, and
Paracetamol, and Indices of Insulin Clearance (Fasting C-Peptide/Insulin), Insulin Sensitivity (Homeostatic Model
Assessment of Insulin Resistance and Hepatic Insulin Sensitivity Index), and b-Cell Function (b-Cell Glucose
Sensitivity and Disposition Index, Calculated Separately for the Upslope, Downslope, and Full Plasma Glucose Curve)
Variable
RYGB,
mean ± SEM
SG,
mean ± SEM
Controls,
mean ± SEM
P value
(ANOVA)
RYGB vs
controls
SG vs
controls
SG vs
RYGB
Hemoglobin A1c, mmol/mol 32 ± 0.9 34 ± 1.4 36 ± 1.1 .13 .11 .45 .64
Fasting PG, mmol/L 4.9 ± 0.1 5.0 ± 0.1 5.3 ± 0.1 .019 .02 .13 .58
Peak PG, mmol/L 10.9 ± 0.4 9.9 ± 0.4 8.8 ± 0.4 <.01 <.01 .09 .13
Nadir PG, mmol/L 3.8 ± 0.2 4.3 ± 0.1 4.4 ± 0.1 .01 .01 .69 .07
DPGmax–min, mmol/L 7.2 ± 1.6 5.6 ± 1.5 4.3 ± 0.4 <.01 <.01 .10 .05
iAUC PG, mmol/L * min 275 ± 109 212 ± 29 153 ± 37 .43 .39 .80 .77
Fasting lactate, mmol/L 1.0 ± 0.1 0.8 ± 0.02 0.9 ± 0.1 .73 .89 .93 .70
Peak lactate, mmol/L 2.1 ± 0.1 1.8 ± 0.1 1.4 ± 0.1 <.01 <.01 <.01 .02
AUC lactate, mmol/L * min 416 ± 15 372 ± 9 333 ± 21 <.01 <.01 .24 .16
Fasting insulin, pmol/L 25 ± 3.5 34 ± 12 54 ± 9.4 .06 .049 .22 .70
Peak insulin, pmol/L 1516 ± 290 669 ± 104 614 ± 137 <.01 <.01 .72 .04
iAUC insulin, nmol/L * min 76.7 ± 14.2 57.7 ± 11.1 52.6 ± 9.6 .43 .37 .87 .65
Fasting C-peptide, pmol/L 460 ± 45 592 ± 83 671 ± 67 .05 .04 .59 .25
Fasting ISR, pmol/kg/min 1.3 ± 0.1 1.6 ± 0.2 1.8 ± 0.1 .05 .04 .59 .27
Peak ISR, pmol/kg/min 23 ± 3.5 16 ± 1.0 13 ± 1.4 .02 .01 .33 .21
iAUC ISR, pmol/kg 1834 ± 224 2025 ± 184 1947 ± 163 .67 1.00 .71 .72
HOMA-IR 0.8 ± 0.1 1.1 ± 0.4 1.8 ± 0.3 .03 .03 .07 .90
HISI 1.5 ± 0.2 1.1 ± 0.1 1.0 ± 0.2 .04 .04 .67 .21
Fasting C-peptide/insulin 20 ± 1 23 ± 2 17 ± 3 .04 .20 .04 .64
Insulinogenic Index 197 ± 40 132 ± 15 141 ± 22 .71 .74 1.00 .78
b-GSup 3.8 ± 0.7 3.0 ± 0.4 3.8 ± 0.4 .43 .69 .40 .87
b-GSdown 3.3 ± 0.5 2.8 ± 0.4 2.9 ±0.2 .76 1.00 .82 .77
DI: b-GSup * 1/HOMA-IR 5.5 ± 1.3 4.8 ± 1.1 3.1 ± 0.7 .16 .14 .47 .72
DI: b-GSdown*1/HOMA-IR 4.8 ± 0.9 4.3 ± 1.0 2.4 ± 0.5 .01 .01 .09 .59
Time to peak paracetamol, min 15 ± 2 36 ± 6 105 ± 19 <.01 <.01 <.01 <.01
b-GS, b-cell glucose sensitivity; DI, Disposition Index; HISI, Hepatic Insulin Sensitivity Index; HOMA-IR, Homeostatic Model
Assessment of Insulin Resistance; PG, plasma glucose.
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synthesis, was equal between groups both in the basal state
and after meal intake (Supplementary Figure 1).
Free Fatty Acids and Glycerol
Free fatty acids and glycerol concentrations were equally
suppressed in all groups (Figure 1, Supplementary
Figure 2). However, the subsequent return toward basal
levels occurred earlier after RYGB. The Ra of glycerol was
comparable between groups in the basal state but less
suppressed after RYGB (47%) compared with the greater
(66%) and more prolonged suppression seen in controls. In
contrast, no difference was found between the Ra of glycerol
between the 2 surgical groups. The Rd of glycerol followed
the same pattern as the Ra.
Gastrointestinal Hormones
Basal concentrations of GLP-1, GIP, and glucagon did not
differ between the groups. Postprandial GLP-1 concentra-
tions differed signiﬁcantly between the groups, with larger=
Figure 1. Plasma glucose concentrations, glucose and glycero
and in response to a mixed-meal in 12 SG-operated (solid trian
and 12 control subjects (white squares, solid line).peaks and iAUCs after RYGB as compared with controls, as
well as >2-fold greater iAUC and peak concentrations after
RYGB vs SG (P < .001, Figure 2, Table 3). The iAUC of GLP-1
was greater in the early postprandial period after SG as
compared with controls (P ¼ .03 for AUC0–60), whereas the
iAUCs for the total postprandial period were comparable.
PYY followed GLP-1 concentrations, with higher peak and
iAUC in RYGB compared with both SG and controls, between
which no difference was seen.
Peak GIP did not differ between groups, but the duration
of GIP secretion was longer and iAUCs were higher in SG
and controls as compared with RYGB. Peak and iAUC of CCK
differed between groups and was highest after RYGB
(Table 3).
The peak and total AUC of glucagon concentrations did
not differ between groups; however, the timing of glucagon
release differed markedly (signiﬁcant time  group inter-
action), with higher glucagon release within the ﬁrst 2 hours
in RYGB (P < .05 vs SG and controls).
The concentrations of total and acylated ghrelin were
lower in the basal state after SG as compared with RYGB andl metabolism, and paracetamol concentrations during fasting
gle, dotted line), 12 RYGB-operated (solid circled, solid line),
Figure 2. (A) ISRs, (B) insulin, (C) glucagon, (D) GLP-1, (E) CCK, (F) GIP, (G) PYY, (H) acyl-ghrelin, and (I) total ghrelin in
response to a mixed-meal in SG-operated (solid triangle, dotted line), RYGB-operated (solid circled, solid line), and control
subjects (white squares, solid line).
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period after SG. In addition, total ghrelin was lower after
RYGB as compared with controls, whereas the difference in
acylated ghrelin between RYGB and controls did not reach
statistically signiﬁcance.
Gastric/Pouch Emptying
Paracetamol absorption was faster in both surgical
groups compared with controls, with shorter times to peak
for plasma paracetamol (Tmax pcm, both P < .01 vs con-
trols), but the kinetics also differed between RYGB and SG,
with signiﬁcantly shorter Tmax pcm after RYGB (P < .01)
(Table 1, Figure 1).
The scintigraphy study included 10 SG-operated, 10
RYGB-operated, and 10 control subjects matched on age
(SG: 41.8 ± 2.8 years, RYGB: 46.2 ± 2.9 years, controls: 45.2
± 2.9 years; ANOVA P ¼ .54), BMI (SG: 31.8 ± 2.0 kg/m2,RYGB: 29.7 ± 1.0 kg/m2, controls: 29.1 ± 1.3 kg/m2; P ¼
.44) and sex (7 women in each group). Tmax pcm (RYGB 32
± 5 minutes, SG 108 ± 17 minutes, controls 165 ± 18 mi-
nutes; P ¼ .03 for SG vs controls and P < .01 for RYGB vs
both SG and controls) and gastric/pouch mean emptying
time (RYGB 11 ± 2 minutes; SG 56 ± 11 minutes; controls
113 ± 8 minutes; P < .01 for all comparisons) differed be-
tween all 3 groups and, importantly, were signiﬁcantly
correlated (Spearman’s r ¼ .79, P < .01).Discussion
In this study, we compared glucose and protein ab-
sorption and metabolism and gastro-entero-pancreatic
hormone secretion between SG- and RYGB-operated sub-
jects, as well as with unoperated matched controls. The
systemic appearances of meal-derived glucose, AA, and
Figure 3. Protein absorption and metabolism. Phe, phenylalanine; Tyr, tyrosine. Data are means ± SEM.
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tween the surgical procedures, with greatly accelerated
digestion and absorption after RYGB. Surprisingly, the
postprandial metabolite kinetics after SG differed markedly
from those observed after RYGB and were only modestly
different from those of the controls. Similarly, gastric/
pouch emptying, evaluated by both scintigraphy and
paracetamol absorption, was greatly accelerated after
RYGB compared with controls, but less so after SG.
Together the accelerated nutrient appearance rates and
paracetamol absorption after RYGB point to a very rapid
intestinal nutrient entry after RYGB conﬁrming data from
studies using both tracers6,7 and scintigraphic tech-
niques.38 Also, postprandial concentrations of insulin, GLP-
1, PYY, and CCK were particularly enhanced after RYGB,
likely related to the accelerated entry of nutrients into the
small intestine. Accelerated gastric emptying has been
demonstrated in some39,40 but not all41 previous studiesafter SG as well, but the 2 procedures have not been
compared directly. We found a marked difference in both
gastric/pouch emptying and nutrient appearance rates
between the 2 surgical procedures. Thus, diverging rates of
intestinal nutrient entry likely explain much of the differ-
ences in the systemic appearance rates of glucose and AAs,
but also in the secretion of insulin, GLP-1, PYY, and CCK
although the direct delivery to the distal gut after RYGB,
but not after SG, may also contribute. The importance of
rate and site of nutrient entry for hormone secretion is
supported by studies in which feeding after reversal of
RYGB or through gastrostomy tubes reversed both GLP-1
and insulin hypersecretion.42,43 Hyperplasia of gut epithe-
lium may result in increased numbers of glucose trans-
porters and higher entry rates, and higher density of
incretin-producing cells have also been reported, primar-
ily after RYGB and not after SG, which could contribute to
the observed differences.44
Table 2.Glucose and Amino Acid Absorption and Metabolism And Lipolysis
Variable
RYGB,
mean ± SEM
SG,
mean ± SEM
Controls,
mean ± SEM
P value
(ANOVA)
RYGB vs
controls
SG vs
controls
SG vs
RYGB
Glucose Metabolism
Basal EGP, mmol/kg FFM/min 18 ± 1 17 ± 1 18 ± 1 .86 .93 .98 .85
EGP suppression, % from basal 60 ± 2 67 ± 2 74 ± 1 <.001 <.01 .05 .04
Peak Ra oral glucose, mmol/kg FFM/min 36 ± 2 27 ± 1 22 ± 2 <.001 <.01 .04 <.01
Time to peak Ra oral glucose, min 39 ± 3 41 ± 5 74 ± 9 .002 .007 <.01 1.00
Oral recovery 360 min, % of ingested
glucose in systemic circulation
72 ± 4 79 ± 5 78 ± 4 .61 .66 1.00 .67
Basal total Ra glucose, mmol/kg FFM/min 18.3 ± 1.1 17.5 ± 1.0 17.8 ± 1.3 .86 .93 .98 .85
Peak total Ra glucose, mmol/kg FFM/min 49.2 ± 3.0 38.2 ± 2.0 32.1 ± 2.0 <.001 <.01 .03 <.01
Basal Rd glucose, mmol/kg FFM/min 18.3 ± 1.1 17.5 ± 1.0 17.8 ± 1.3 .86 .93 .98 .85
Peak Rd glucose, mmol/kg FFM/min 44.8 ± 2.8 38.1 ± 2.5 31.2 ± 2.2 .002 .001 .11 .12
Lipolysis
Suppression of FFA, % from basal 72 ± 6 72 ± 2 69 ± 5 .74 .81 .76 .99
Basal Ra glycerol, mmol/kg fat/min 11.0 ± 1.0 9.5 ± 0.8 10.4 ± 1.1 0.54 — — —
Suppression Ra glycerol, % from basal 47 ± 4 58 ± 3 66 ± 3 .007 .005 .29 .15
Protein metabolism
Fasting Phe, mmol/L 52 ±2.9 51 ± 1.8 58 ±1.7 .11 .11 .09 .99
Peak Phe, mmol/L 97 ± 3.8 73 ± 4.3 72 ± 1.2 <.001 <.01 .99 <.01
AUC Phe, mmol/L  min 20 ± 1.1 20 ± 0.6 22 ± 0.5 .09 .14 .14 1.00
Peak Ra oral Phe, mmol/kg FFM/min 0.37 ± 0.04 0.23 ± 0.04 0.17 ± 0.01 <.001 <.01 .22 <.01
Time to peak Ra or Phe, min 38 ± 2 93 ± 13 176 ± 14 <.001 <.01 <.01 <.01
Oral recovery 60 min, % of ingested phe 30 ± 2.2 13 ± 3.3 4 ± 0.5 <.001 <.01 .01 <.01
Oral recovery 360 min, % of ingested phe 67 ± 3 70 ± 4 67 ± 4 .64 1.00 .70 .68
Basal total Ra Phe, mmol/kg FFM/min 0.77 ± 0.04 0.80 ± 0.06 0.91 ± 0.03 .02 .02 .07 .82
Peak total Ra Phe, mmol/kg FFM/min 1.25 ± 0.08 1.0 ± 0.10 0.98 ± 0.04 .001 .009 .88 .03
AUC total Ra Phe, mmol/kg FFM 272 ± 16 281 ± 19 306 ± 14 .14 .15 .27 .93
Basal whole-body protein synthesis,
mmol/kg FFM/min
0.71 ± 0.04 0.74 ± 0.06 0.84 ± 0.03 .02 .02 .08 .82
Peak whole-body protein synthesis,
mmol/kg FFM/min
1.11 ± 0.08 0.93 ± 0.10 0.91 ± 0.04 .07 .09 .96 .15
AUC whole-body protein synthesis,
mmol/kg FFM
252 ± 15 261 ± 19 284 ± 14 .16 .15 .35 .87
Basal whole-body protein degradation
(Ra endogenous Phe), mmol/kg FFM/min
0.77 ± 0.04 0.80 ± 0.06 0.91 ± 0.03 .02 .02 .07 .82
AUC whole-body protein degradation
(AUC Ra endogenous Phe), mmol/kg FFM
241 ± 13 246 ± 16 272 ± 12 .08 .08 .16 .92
Basal net protein balance, g protein/d –0.9 ± 0.1 –0.8 ± 0.1 –1.0 ± 0.1 .96 .99 .95 .99
AUC net protein balance, g protein/d 154 ± 30 184 ± 36 138 ± 44 .67 1.00 .70 .74
Basal Ra urea, mmol/kg FFM/min 5.1 ± 0.3 4.0 ± 0.5 5.1 ± 0.5 .24 .99 .30 .32
AUC total Ra urea, mmol/kg FFM 1768 ± 101 1334 ± 166 1634 ± 146 .11 .92 .26 .12
Phe, phenylalanine.
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trols and both surgical groups, but we also found a marked
difference between RYGB and SG. The peak oral Ra of
glucose was 64% higher after RYGB and 21% higher after
SG compared with controls, and a larger proportion of
ingested glucose appeared in the systemic circulation during
the ﬁrst postprandial hour after RYGB. Also, elevated lactate
formation was found, especially after RYGB, probably
reﬂecting glucose ﬂuxes.45 In contrast, the oral recovery of
glucose did not differ between groups during the full study
day—a ﬁnding that does not support enhanced splanchnic
glucose disposal as a major contributor to improved glyce-
mic control after RYGB, as proposed by others.44 In a pre-
vious study,9 comparable improvements in insulin
sensitivity were observed after an approximately 20%
weight loss induced by RYGB or SG, and differences betweenthe groups for peak Ra oral glucose appeared to exist with
numerically higher values after RYGB9 in agreement with
our ﬁndings.
The enhanced GLP-1 secretion after RYGB is in line with
numerous previous reports, but surprisingly, the iAUC of
GLP-1 in SG-operated subjects did not differ from that of
controls, although a slightly enhanced response was
observed just after meal intake. This is in agreement with a
few previously published reports,20–22 but it is in direct
contrast to other studies reporting equally enhanced GLP-1
after SG and RYGB.17–19 Peak CCK concentration was also
considerably higher after RYGB compared with SG and
controls, whereas peak GIP concentrations were comparable
after both surgical procedures, although the duration of the
GIP response was signiﬁcant longer in the SG-operated
subjects than in RYGB.
Figure 4. Selected plasma AAs concentrations. Data are means ± SEM.
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tween RYGB and SG in other studies can be attributed to
various factors: differences in surgical techniques with
different limb lengths,18,19 small group sizes,18,19 and the
timing of blood sampling because frequent postprandial
blood sampling is essential in detecting the peaks of
rapidly degradable hormones.18,19,46 Inaccuracy of certain
commercial assays can also be a matter of concern and,furthermore, the type and texture of ingested nutrients
affect the responses seen.
In this study, glucagon concentrations followed the AA
absorption and plasma AA concentrations closely, with an
early increase after RYGB and a later increase in controls, in
agreement with a previously proposed feedback loop.47
Conﬁrming previous ﬁndings, ghrelin was lower after
SG,19 which, combined with slightly higher levels of PYY,
Table 3.Gastrointestinal Hormones
Variable
RYGB,
mean ± SEM
SG,
mean ± SEM
Controls,
mean ± SEM
P value
(ANOVA)
RYGB vs
controls
SG vs
controls
SG vs
RYGB
Fasting GLP-1, pmol/L 17 ± 3 15 ± 1 18 ± 1 .51 .98 .54 .62
Peak GLP-1, pmol/L 147 ± 9 63 ± 10 42 ± 8 <.001 <.01 .05 <.01
iAUC GLP-1, nmol/L * min 8.192 ± 0.847 3.622 ± 0.730 2.444 ± 0.408 <.001 <.01 .48 <.01
Fasting GIP, pmol/L 12 ± 2 11 ± 1 11 ± 1 .92 .98 .97 .91
Peak GIP, pmol/L 128 ± 8 120 ± 13 95 ± 11 .09 .08 .33 .68
iAUC GIP, nmol/L * min 6.2 ± 0.5 12.1 ± 1.9 11.8 ± 1.3 .004 .03 .98 .02
Fasting PYY, pmol/L 18 ± 1.1 13 ± 1.0 16 ± 1.3 .01 .37 .14 .01
Peak PYY, pmol/L 70 ± 6.4 32 ± 4.3 23 ± 1.5 <.001 <.01 .16 <.01
iAUC PYY, pmol/L * min 5821 ± 949 3311 ± 751 1017 ± 420 <.001 <.01 .08 .05
Fasting glucagon, pmol/L 4 ± 1 3 ± 1 5 ± 1 .18 .70 .16 .52
Peak glucagon, pmol/L 16 ± 2 10 ± 1 12 ± 2 .10 .18 .98 .12
AUC glucagon, pmol/L * min 2339 ± 283 1917 ± 354 2606 ± 555 .29 .97 .42 .31
Fasting CCK, pmol/L 0.4 ± 0.3 0.5 ± 0.2 1.0 ± 0.9 0.03 .01 .06 .45
Peak CCK, pmol/L 12.8 ± 7 7.0 ± 3 5.0 ± 5 <.001 <.01 .02 <.01
iAUC CCK, pmol/L * min 623 ± 317 383 ± 181 426 ± 195 .046 .09 .40 .02
Fasting acylated ghrelin, pg/mL 42 ± 5 24 ± 3 51 ± 9 .006 .82 .007 .03
AUC acylated ghrelin, ng/mL 15 ± 1 9 ± 1 20 ± 3 <.001 .13 <.001 .05
Fasting total ghrelin, pg/mL 936 ± 86 555 ± 55 1325 ± 175 <.001 .049 <.001 <.01
AUC total ghrelin, ng/mL 473 ± 34 281 ± 32 716 ± 93 <.001 .01 <.001 <.01
AUC, area under the curve.
1638 Svane et al Gastroenterology Vol. 156, No. 6
CLINICAL
ATGLP-1, and CCK, might explain some of the weight-reducing
effects of SG. This is in contrast to RYGB, in which exag-
gerated concentrations of L-cell hormones seem impor-
tant.13 Accordingly, different combinations of hormonal
changes could hypothetically contribute to the appetite-
regulating effects of the 2 procedures. The role of ghrelin
needs further investigation because mice lacking ghrelin
signaling and their wild-type counterparts had comparable
weight losses after SG.48
Notably, all participants were glucose-tolerant before the
procedures. Therefore, differences in b-cell glucose sensi-
tivity between the groups were not expected.14,46 Never-
theless, when relating b-cell glucose sensitivity to ambient
insulin sensitivity, the surgical groups displayed increased
b-cell function (ie, disposition index) compared with con-
trols. Although GLP-1 was excessively higher after RYGB, SG-
operated subjects also demonstrated enhanced GLP-1 and
GIP early postprandially, which, in combination with a
steeper increase in glucose concentrations, would be ex-
pected to elicit augmented insulin secretion. Furthermore,
GIP responses were considerably prolonged in SG compared
with RYGB. Importantly, the dose–response relationship
between the endogenously secreted incretins and the
potentiation of glucose-stimulated insulin secretion remains
unknown in these groups of individuals.
Postprandial AA kinetics have not been assessed after SG
previously, and although it occurred earlier, the peak oral
Ra of phenylalanine was not elevated after SG compared
with controls. This indicates unaltered protein digestion and
absorption after SG, in contrast to the accelerated absorp-
tion of protein (with a 118% larger peak rate) seen after
RYGB in this study and in our previous study.7
This study adds substantial new knowledge about pro-
tein metabolism after RYGB and SG7 via the estimation ofwhole-body protein balance. We observed a fast and tran-
sient rise in total AA concentration, and a correlated rise in
the systemic appearance of meal-derived AAs after RYGB.
This conﬁrms that the postprandial increase in AAs origi-
nates from ingested food and not from increased protein
degradation,7 and suggests that the accelerated protein
digestion and absorption rates persist years after RYGB,
when patients are weight-stable. Protein kinetics differed
markedly between RYGB and SG, and SG-operated subjects
did not differ from the control group in this respect.
Nevertheless, the 6-hour postprandial oral recovery of
ingested protein was comparable between all groups, which
indicates that no differences in splanchnic extraction of AAs
or protein malabsorption exist in either surgical group.
The hydroxylation of phenylalanine to tyrosine is an
index of phenylalanine oxidative loss and paralleled the
accelerated appearance of orally ingested phenylalanine.
Likewise, protein synthesis was greatly stimulated in the
early postprandial period only after RYGB, followed by later
suppression. Because of these 2 opposing processes, net
protein synthesis ended up being similar in all groups. In
other words, the proportion of ingested phenylalanine tar-
geted to protein synthesis and to oxidative loss, respec-
tively, was similar in the 3 groups during the entire
postprandial period. However, the net-positive protein bal-
ance lasted only 2.5 hours after RYGB, compared with 4
hours after SG and in controls, and the consequences of this
more pronounced but shorter anabolic phase require
further investigation. Taken together, our ﬁndings support
effective digestion and absorption of protein after RYGB and
early stimulation of protein synthesis. Obviously, inadequate
protein intake can still lead to a negative nitrogen balance.
Loss of muscle mass is a natural adaptation to major weight
loss,49 but the present study does not support any speciﬁc
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studies demonstrating higher FFM percentages after both
RYGB and SG compared with unoperated controls, incon-
sistent with major FFM depletion after surgery.50 Instead,
the loss of FFM seems comparable to what is expected due
to the weight loss itself.51
The cross-sectional design of our study has the advan-
tage that we were able to examine patients in the weight-
stable phase and to obtain matching for both pre- and
postoperative BMI to minimize the confounding effect of
differing postoperative weight losses. Hence, our ﬁndings
represent the late metabolic effects of surgery, which might
differ signiﬁcantly from the acute effects within the ﬁrst
postoperative year when weight loss is still ongoing. This
cross-sectional design poses some limitations because the
ﬁndings are associations and not causal relationships.
Accordingly, these hypothesis-generating ﬁndings need to
be conﬁrmed in future prospective or interventional studies.
The magnitudes of the weight losses after SG and RYGB are
debated. Some studies report similar weight losses,3,21 while
others report a smaller weight loss after SG.2,5,52 If we as-
sume that SG-operated patients have similar or slightly less
weight loss, then, if anything, our selection of patients would
underestimate differences between SG and RYGB, making
the observed differences a conservative estimate. Only
participants without prior diabetes were included, which
should be considered when assessing potential mechanisms
related to diabetes remission. Finally, the use of a liquid
meal in our study meal could have inﬂuenced the results
and future studies comparing the surgical procedures in
patients with diabetes and the use of meals also consisting
of solid components would be of interest.
Conclusions
Postprandial glucose and protein absorption and meta-
bolism, as well as patterns of gastro-entero-pancreatic
hormone secretion differed markedly between RYGB- and
SG-operated subjects matched in terms of postoperative
weight loss. We have shown enhanced systemic glucose
appearance and more exaggerated glucose excursions after
RYGB. Also, accelerated protein digestion, absorption, and
whole-body protein synthesis were seen after RYGB. In
contrast, protein metabolism after SG largely resembled that
of unoperated subjects. The differences between the pro-
cedures may be explained by the greatly accelerated pouch
emptying and more distal nutrient delivery after RYGB. Both
procedures altered postprandial gastrointestinal hormone
secretions, with exaggerated secretion of GLP-1, PYY, and
CCK, especially after RYGB, whereas ghrelin was lower and
GIP responses more prolonges after SG. These observations
may be important for our understanding of the clinical ef-
fects of the 2 surgical procedures.
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Supplementary Material
Tracer Calculations and Equations
Total Ra and Rd of glucose, phenylalanine, and tyrosine
were estimated using non–steady-state equations using
enrichments of [6,6-D2] glucose, L-[ring-
2D5] phenylalanine
and L-[ring 3,5-D2]tyrosine, respectively:
Total Ra ¼ F  Vd x CðtÞ x
DEiv
Dt
EivðtÞ
Total Rd ¼ Total Ra Vd x DC
Dt
F is the infusion rate of the intravenous tracer,
Vd is the distribution volume (set to 0.07),
C(t) is the mean plasma concentrations of glucose,
phenylalanine or tyrosine between two time points,
DEiv
Dt is the time-dependent variation in plasma enrich-
ments (tracer-to-tracee ratio) derived from the intravenous
tracers,
Eiv(t) is the mean of plasma enrichments derived from
the intravenous tracers between 2 time consecutive time
points, and
DC
Dt is the time-dependent variation in plasma concen-
trations of glucose, phenylalanine or tyrosine.
Oral appearance rate of phenylalanine (oral Raphe) was
calculated from plasma [15N Phe]-enrichments (tracer-to-
tracee ratios) multiplied with Total Ra Phe and was
corrected for time-dependent variations in plasma [15N
Phe]-enrichments:
Oral Ra Phe ¼ Total Ra Phe x EoralðtÞ þ Vd x
DEoral
Dt
Eprotein
Eoral(t) is the mean plasma enrichment of the oral
[15N Phe] tracer,
DEoral
Dt is the time-dependent variation in plasma enrich-
ments derived from the oral[15N Phe] tracer, and
Eprotein is the [15N Phe] enrichment in the ingested
protein (w0.12).
Endogenous Ra was calculated as:
Endo Ra ¼ Total Ra – Oral Ra.
Supplementary Figure 1. Ra of urea in 12 SG-operated
subjects (solid triangle, dotted line), 12 RYGB-operated
subjects (solid circled, solid line), and 12 control subjects
(white squares, solid line).
Supplementary Figure 2. Plasma concentrations of FFA in
the basal state and after ingestion of a liquid mixed meal at
time ¼ 0 in 12 SG-operated subjects (solid triangle, dotted
line), 12 RYGB-operated subjects (solid circled, solid line),
and 12 unoperated control subjects (solid squares, solid line).
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